What is NBO Pharma Inc?
Incorporated in 2021, NBO Pharma Inc operates at the intersection of pharmaceutical innovation and orphan drug development. The company is primarily focused on the treatment of Idiopathic Intracranial Hypertension (IIH), a condition currently lacking FDA-approved pharmacological interventions. By leveraging a strategic repurposing model, NBO Pharma is advancing an intranasal formulation of octreotide acetate. This proprietary delivery mechanism aims to enhance bioavailability, providing a targeted therapeutic pathway for patients suffering from this debilitating neurological disorder. The company's current market position is defined by its rigorous adherence to clinical trial protocols and its commitment to navigating the complex regulatory landscape of orphan drug designation.
How much funding has NBO Pharma Inc raised?
NBO Pharma Inc has raised a total of $7.6M across 1 funding round:
Stock/Share Issuance
$7.6M
Stock/Share Issuance (2026): $7.6M, investors not publicly disclosed
Key Investors in NBO Pharma Inc
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for NBO Pharma Inc?
Following this major strategic investment, NBO Pharma Inc is expected to prioritize the expansion of its clinical trial infrastructure. The capital will likely be deployed to scale manufacturing capabilities for its intranasal octreotide formulation and to support the necessary data collection required for regulatory submissions. As the company transitions from early-stage development to more advanced clinical phases, the focus will shift toward establishing commercial viability and securing long-term partnerships within the biotech ecosystem. Stakeholders should anticipate further updates regarding trial milestones and potential expansion into secondary indications as the firm leverages its current financial runway to solidify its leadership in the IIH therapeutic space.
See full NBO Pharma Inc company page
